[go: up one dir, main page]

WO2009071096A3 - Combination of medical and physical cooling treatment of ischemic effects - Google Patents

Combination of medical and physical cooling treatment of ischemic effects Download PDF

Info

Publication number
WO2009071096A3
WO2009071096A3 PCT/DK2008/050294 DK2008050294W WO2009071096A3 WO 2009071096 A3 WO2009071096 A3 WO 2009071096A3 DK 2008050294 W DK2008050294 W DK 2008050294W WO 2009071096 A3 WO2009071096 A3 WO 2009071096A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
agonists
hypothermia
receptor agonists
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2008/050294
Other languages
French (fr)
Other versions
WO2009071096A2 (en
Inventor
Jacob Gotfredsen
Uno Jakob Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROKEY AS
Original Assignee
NEUROKEY AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROKEY AS filed Critical NEUROKEY AS
Publication of WO2009071096A2 publication Critical patent/WO2009071096A2/en
Publication of WO2009071096A3 publication Critical patent/WO2009071096A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of combination of physical /mechanical hypothermia therapy and a pharmaceutical composition comprising at least one compound selected among a (1) vanilloid receptor agonists, capsaicinoids or capsaicinoid-like agonists reaching and binding to vanilloid receptors, and (2) cannabinoids or cannabimimetic agonists reaching and binding to cannabinoid receptors, and (3) adenosine receptor agonists, and (4) neurotensin receptor agonists, and (5) thyroxine derivatives, and (6) cytochrome c oxidase inhibitors and (7) oxygen tension reducers thereby inducing hypothermia, thus benefiting patients suffering from illnesses characterized by tissue anoxia.
PCT/DK2008/050294 2007-12-05 2008-12-05 Combination of medical and physical cooling treatment of ischemic effects Ceased WO2009071096A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200701744 2007-12-05
DKPA200701744 2007-12-05
DKPA200701742 2007-12-05
DKPA200701742 2007-12-05
DKPA200801104 2008-08-15
DKPA200801104 2008-08-15
DKPA200801105 2008-08-15
DKPA200801105 2008-08-15

Publications (2)

Publication Number Publication Date
WO2009071096A2 WO2009071096A2 (en) 2009-06-11
WO2009071096A3 true WO2009071096A3 (en) 2010-01-07

Family

ID=40679505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050294 Ceased WO2009071096A2 (en) 2007-12-05 2008-12-05 Combination of medical and physical cooling treatment of ischemic effects

Country Status (1)

Country Link
WO (1) WO2009071096A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155300A1 (en) 2007-04-05 2010-02-24 Velomedix, Inc Automated therapy system and method
CA2693774A1 (en) 2007-07-09 2009-01-15 Velomedix, Inc. Hypothermia devices and methods
US9622670B2 (en) 2010-07-09 2017-04-18 Potrero Medical, Inc. Method and apparatus for pressure measurement
GB2504263B (en) * 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
EP3732994B1 (en) 2013-02-08 2022-11-09 General Mills, Inc. Reduced sodium food products
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102368A1 (en) * 2002-11-27 2004-05-27 Katz Laurence M. Methods of treating cerebral ischemia
WO2007140786A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008040360A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102368A1 (en) * 2002-11-27 2004-05-27 Katz Laurence M. Methods of treating cerebral ischemia
WO2007140786A1 (en) * 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008040360A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of hypothermia inducing drugs to treat ischemia

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
APPENDINO G ET AL: "TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 13, no. 12, 1 December 2003 (2003-12-01), pages 1825 - 1837, XP002487646, ISSN: 1354-3776 *
BONFILS P K ET AL: "Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB, vol. 49, no. 5, 1 October 2006 (2006-10-01), pages 508 - 518, XP025067906, ISSN: 0197-0186, [retrieved on 20061001] *
DING ET AL: "Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1065, no. 1-2, 14 December 2005 (2005-12-14), pages 147 - 151, XP005206563, ISSN: 0006-8993 *
HAYAKAWA KAZUHIDE ET AL: "Delta(9)-tetrahydrocannabinol (Delta(9)-THC) Prevents cerebral infarction via hypothalamic-independent hypothermia", LIFE SCIENCES, vol. 80, no. 16, March 2007 (2007-03-01), pages 1466 - 1471, XP002551820, ISSN: 0024-3205 *
LEKER RONEN R ET AL: "Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 34, no. 8, 1 August 2003 (2003-08-01), pages 2000 - 2006, XP002451424, ISSN: 0039-2499 *
MAULER FRANK ET AL: "BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury", CNS DRUG REVIEWS, BRANFORD, CT, US, vol. 9, no. 4, 1 January 2003 (2003-01-01), pages 343 - 358, XP002451422, ISSN: 1080-563X *
OLSEN T S ET AL: "Therapeutic hypothermia for acute stroke", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 2, no. 7, 1 July 2003 (2003-07-01), pages 410 - 416, XP004810147, ISSN: 1474-4422 *
PEGORINI S ET AL: "Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS, vol. 144, 1 January 2005 (2005-01-01), pages 727 - 735, XP007904383, ISSN: 0007-1188 *
RAWLS S M ET AL: "CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalen yl-carbonyl) -6H-pyrrolo[3,2,1 ij]quinolin-6-one]-induced hypothermia", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 301, no. 3, 1 January 2002 (2002-01-01), pages 963 - 968, XP002451426, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
WO2009071096A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2008040361A3 (en) Use of a combination of hypothermia inducing drugs
WO2010015260A3 (en) Administration by infusion for the treatment of ischemic effects
WO2008040360A3 (en) Use of hypothermia inducing drugs to treat ischemia
WO2009124552A3 (en) Use of a combination of hypothermia inducing drugs
WO2009071096A3 (en) Combination of medical and physical cooling treatment of ischemic effects
BRPI0013478B8 (en) medicament comprising pde inhibitor and use of roflumilast
MX2009012000A (en) Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis.
EA200800056A1 (en) CANNABINOID ACTIVE PHARMACEUTICAL INGREDIENT FOR MEDICINAL FORMS
NO20072461L (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
DE60331236D1 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DIABETES
BRPI0519803A2 (en) methods for purifying trans - (-) - delta9-tetrahydrocannabinol and trans - (+) - delta9-tetrahydrocannabinol
WO2009071094A3 (en) Combination treatment of ischemic effects
MX2009011900A (en) Diabetic wound healing.
ZA200904704B (en) Treatment of cachexia
ATE399543T1 (en) NEW SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND FORMOTEROL
WO2009124551A3 (en) Use of vanilloid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
ATE399544T1 (en) SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND (R,R)-FORMOTEROL
EA201000739A1 (en) NEW MEDICAL APPLICATION OF SALTS 3- (2,2,2-TRIMETHYL HYDRAZINIUM) PROPIONATE
IS8373A (en) Use of oxcarbazepine to treat diabetes due to diabetes mellitus and to improve sleep
BR0214776A (en) Combination of a selective pde4 inhibitor and a beta-2 adrenergic receptor agonist
PT1490049E (en) CITALOPRAM FOR THE TREATMENT OF THE HIGH SANGUINIA PREVENTION.
NO20062369L (en) Use of a pyrazole derivative for the manufacture of medications to prevent and treat dyslipidemia and diseases associated with dyslipidemia and / or obesity
IS6976A (en) Combined dose of cyclooxygenase (COX) inhibitor, vitamin D3 including analogues and metabolites and / or calcium to prevent epithelial cancer
CY1115890T1 (en) INSPIRED PHARMACEUTICAL FORMS OF DOUBLE ACTION PROVIDING BOTH IMMEDIATE PROTECTION AND MAINTENANCE RELEASE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856983

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14.09.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08856983

Country of ref document: EP

Kind code of ref document: A2